Susceptibility profile and MIC90 of 69 IRPA samples and the analysis according to MBL production.
| Overall (n = 69) | MBL positive (n = 21) | MBL negative (n = 48) | ||||||||||
| Antimicrobial | %S | %I | %R | MIC90(µg/mL) | %S | %I | %R | MIC90(µg/mL) | %S | %I | %R | MIC90(µg/mL) |
| Aztreonam | 40.6 | 13 | 46.4 | > 16 | 85.7 | 9.5 | 4.8 | 16 | 20.8 | 14.6 | 64.6 | > 16 |
| Ceftazidime | 14.5 | 4.3 | 81.2 | > 16 | 0 | 0 | 100 | > 16 | 20.8 | 6.3 | 72.9 | > 16 |
| Cefepime | 13 | 18.8 | 68.2 | > 16 | 0 | 0 | 100 | > 16 | 18.8 | 27.1 | 54.1 | > 16 |
| Amikacin | 43.5 | 4.3 | 52.2 | > 32 | 4.8 | 0 | 95.2 | > 32 | 60.4 | 6.3 | 33.3 | > 32 |
| Gentamicin | 34.8 | 8.7 | 56.5 | > 8 | 0 | 0 | 100 | > 8 | 50 | 12.5 | 37.5 | > 8 |
| Tobramycin | 43.5 | 1.4 | 55.1 | > 8 | 0 | 0 | 100 | > 8 | 62.5 | 2.1 | 35.4 | > 8 |
| Imipenem | 0 | 0 | 100 | > 8 | 0 | 0 | 100 | > 8 | 0 | 0 | 100 | > 8 |
| Meropenem | 7.2 | 4.4 | 88.4 | > 8 | 0 | 0 | 100 | > 8 | 10.4 | 6.3 | 83.3 | > 8 |
| Ciprofloxacin | 14.5 | 0 | 85.5 | > 2 | 0 | 0 | 100 | > 2 | 20.8 | 0 | 79.2 | > 2 |
| Piperacilin | 47.8 | 0 | 52.2 | > 64 | 76.2 | 0 | 23.8 | > 64 | 35.4 | 0 | 64.6 | > 64 |
| Pip / Tazo | 47.8 | 0 | 52.2 | > 64 | 76.2 | 0 | 23.8 | > 64 | 35.4 | 0 | 64.6 | > 64 |
| Tic / Ac. Clav. | 28.9 | 0 | 71.1 | > 64 | 33.3 | 0 | 66.7 | > 64 | 27.1 | 0 | 72.9 | > 64 |
| Colistin (E‐test®) | 94.2 | 1.5 | 4.3 | 2 | 90.5 | 4.7 | 4.8 | 2 | 95.8 | 2.1 | 2.1 | 2 |
%S: sensitivity percentage; %I: intermediate percentage; %R: resistance percentage; Pip: piperacilin; Tazo: tazobactam; Tic: ticarcilin; Ac. Clav: clavulanic acid.